Kevin Jickling
About Kevin Jickling
Kevin Jickling serves as the Director of Trade Strategy & Operations for US Health Systems at Kite Pharma, bringing extensive experience in technical operations and commercial settings within the cell and gene therapy sector. He has held various roles at Abbott and Kite Pharma, focusing on supply chain management and leveraging insights to enhance organizational effectiveness.
Work at Kite Pharma
Kevin Jickling currently serves as the Director of Trade Strategy & Operations for US Health Systems at Kite Pharma, a position he has held since 2024. Prior to this role, he worked as the Associate Director of Supply Chain, focusing on Logistics and Order Management from 2021 to 2023. He also held the position of Associate Director for Value & Access in US Trade Strategy and Operations from 2023 to 2024. His work at Kite Pharma emphasizes leveraging patient and provider insights to implement changes within the organization.
Experience at Abbott
Kevin Jickling has a background in operations at Abbott, where he held multiple roles. He worked as an Operations Supervisor for Powder Stickpack and Liquid 8oz Can Filling and Packaging in Abbott Nutrition for four months in 2017. He also served as a Production Scheduler in Abbott Nutrition for one year from 2016 to 2017, and as a Program Manager in Sourcing for Abbott Medical Devices from 2017 to 2019. His diverse roles at Abbott contributed to his expertise in technical operations and commercial settings.
Education and Expertise
Kevin Jickling earned a Bachelor of Arts in Supply Chain Management from Michigan State University, where he studied from 2010 to 2014. His educational background provides a solid foundation for his career in supply chain and operations within the biotech sector. His expertise spans clinical, pre-commercial, launch, and post-commercial stages in cell and gene therapy.
Professional Skills and Leadership Style
Kevin Jickling is recognized for his energetic communication and leadership style. He emphasizes collaboration with both internal and external partners, which enhances his effectiveness in driving strategic initiatives. His ability to leverage insights from patients and providers is a key aspect of his approach to improving operations within biotech organizations.